Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JW0202 + C2202
- Development stage
- Unknown
- Lead developer
- JW Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**JW0202 + C2202** refers to the combination of two small molecule drugs studied together for their pharmacokinetic and safety profile in healthy volunteers and evaluated as part of combination therapy in type 2 diabetes mellitus. JW0202 and C2202 are both investigational drugs developed by JW PHARMACEUTICAL with ongoing research into their efficacy and safety as adjuncts for patients with inadequate glycemic control.
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)DPP8 (Dipeptidyl peptidase 8)DPP9 (Dipeptidyl Peptidase 9)FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on JW0202 + C2202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JW0202 + C2202.